Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen Insensitivity
NCT ID: NCT04708431
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
650 participants
OBSERVATIONAL
2021-04-29
2040-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Androgen effects in humans are usually (but not always) mediated by the androgen receptor which is coded for by the androgen receptor gene (AR gene). Androgen Insensitivity Syndrome (AIS) is a rare condition in which the body cannot sense the male hormones in the blood or tissue. Both women and men can be affected by AIS. Researchers want to learn more about the health of people with AIS over time.
With a natural history study in individuals with AIS, data and tests may provide information regarding health risks (including the risks and benefits of gonadectomy and best ways to monitor for tumor) and optimal management of individuals with AIS as well as elucidate the role of the androgen receptor in human health. This study does not involve any interventions and we can provide clinical care while collecting data.
Objective:
The objective of this natural history study is to describe and define a comprehensive phenotype (characteristic) of patients with AIS based on confirmed androgen receptor (AR) gene difference. We will evaluate hormones, bone density and markers, cardiovascular and metabolic parameters, as well as quality of life and tumor formation risk and evaluation. The purpose is to obtain a better understanding of the overall health issues that people with AIS may have through the study procedures listed.
Eligibility:
People ages 0-99 with AIS and their adult relatives
Design:
Participants will go through a series of study procedures for data and specimen collection. This will be done to understand how AIS affects individuals since the androgen receptor is found in many tissues in the body including skin, bone, muscle, and the neurologic, immune and metabolic systems. All tests will be performed by skilled and trained study professionals.
Participants will be screened with:
Medical history
Physical exam
Medical record review
Lab tests.
Participants will have physical exams. Their body measurements will be taken. They will have blood and urine tests. They will have electrocardiograms to check heart health. They may complete questionnaires. They may have an Oral Glucose Tolerance Test.
Participants may have x-rays and HRpQCT scans taken of the hand, wrist, and other bones.
Participants will have body scans to measure bone thickness.
Participants will have magnetic resonance imaging (MRI) or sonogram of the pelvis. For MRI, they may get a contrast agent via intravenous (IV) catheter.
Adult participants may have the following:
MR elastography. It uses MRI and low-frequency vibrations to map stiffness of body tissues.
MR spectroscopy. It uses MRI to take pictures of chemicals in the liver and body fat.
Cardiac computed tomography scan. It uses x-rays to make pictures of the heart. Participants may get a contrast agent via IV.
Optional genital exam.
Participants will have visits every 1-2 years. Participation lasts indefinitely.
Adult relatives will also be invited to participate but will have only 1 visit. It will include some of the above tests.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objectives:
Primary Objectives:
To define and describe a comprehensive phenotype of patients with androgen insensitivity (based on confirmed androgen receptor
(AR) gene difference), including hormonal, metabolic, immunologic, and cardiovascular aspects of AIS, as well as quality life and tumor formation risk and evaluation.
Secondary Objectives:
1. Bone Health:
\- Follow a large population of patients with androgen receptor abnormalities for:
* Longitudinal assessment of bone mineral density (BMD) before and after gonadectomy
* Development of normative values for dual-energy X-ray absorptiometry (DEXA) and high-resolution peripheral quantitative computed tomography (HRpQCT) scans in individual with complete androgen insensitivity syndrome (CAIS) and family members.
* Studies to determine bone geometry, strength and shape,
* Studies to determine muscle-skeletal unit inferences
* Studies to evaluate skin tone
* Evaluation of bone accrual from infancy to adolescence
2. Metabolic and Immune Abnormalities:
\- Follow a large population of patients with androgen receptor abnormalities for studies of metabolic abnormalities and auto-immune disease screening
* Metabolic syndrome,
* Insulin resistance
* Cardiovascular markers
* Endometabolic imaging
* Autoimmune screening tests
3. Testicular Tumor Risk and Monitoring:
\- Follow a large population of patients with androgen receptor abnormalities in order to:
\-- Describe the typical and atypical appearance of testes on ultrasound and magnetic resonance imaging (MRI) in young individual with
CAIS.
* Evaluate gonadal tumor markers as a tool to assess for gonadal tumor.
\- When individuals with androgen receptor abnormalities decide to undergo gonadectomy, perform tissue evaluation in order to:
* Investigate the pathophysiology of gonadal tumor formation
* Assess fertility potential in testis of individual with androgen receptor abnormalities
4. Quality of Life:
* Follow a large population of patients with androgen receptor abnormalities to characterize quality of life measures throughout the lifespan
* Evaluate the effects of androgen receptor abnormalities on individual s sexual function. Compare sexual function in adult individuals with androgen receptor abnormalities to individual with classic congenital adrenal hyperplasia (CAH) and unaffected individual of
similar ages.
5. Hormone Replacement:
\- Evaluate different types and delivery of hormone replacement therapy on quality of life, sexual function, bone health and metabolic parameters in individual who have undergone gonadectomy
6. Follow a sample population of relatives of individuals with androgen insensitivity syndrome (AIS) in order to assess the effects of AR gene difference carrier status phenotype including hormonal, metabolic, immunologic, quality of life, and tumor formation. Family members without AR gene abnormalities will serve as controls.
Follow a large population of patients with AIS for referral to future treatment studies.
Endpoints:
Primary Endpoint: Longitudinal evaluation of 500 individuals with AIS.
Secondary:
* DEXA and HRpQCT scans and bone metabolism markers will be evaluated longitudinally in all individuals with AIS. Additionally, these will be correlated with muscle grip and skin tone studies.
* Compare metabolic parameters in all individuals with AIS.
* Compare gonadal tissue with MRI or ultrasound in all individuals with AIS.
* Evaluate Quality of life with Quality of Life (QoL) questionnaire.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Female subjects relatives who are carriers of the AR gene difference
We will enroll 50 female subjects relatives AIS subjects who are carriers of the AR gene difference
No interventions assigned to this group
Female subjects relatives who are not carriers of the AR gene
We will enroll 50 female subjects relatives of AIS subjects who are not carriers of the AR gene.
No interventions assigned to this group
Healthy male subjects relatives
We will enroll 50 healthy male subjects of AIS relative subjects
No interventions assigned to this group
Subjects with androgen receptor mutations
500 Subjects with confirmed androgen receptor mutations
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Individuals ages 0-99 years old with known androgen insensitivity based on pathologic androgen receptor gene mutation or based on clinical diagnosis of complete androgen insensitivity (CAIS) based on 46 XY karyotype, presence of testis, absence of uterus, high testosterone without signs of virilization at birth or during puberty and/or multiple members in the family also presenting with clinical CAIS.
2. Identify as male or female
3. Patients with both complete, partial and mild androgen insensitivity are eligible
4. Stated willingness to comply with all study procedures and availability for the duration of the study
5. Ability of subject or guardian to understand and the willingness to sign and date a written informed consent document.
1\) Adult Relatives of patients with AIS
Exclusion Criteria
2. Patients with significant non-endocrine medical conditions.
1\) Patients with significant non-endocrine medical conditions.
1 Year
99 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Veronica Gomez-Lobo, M.D.
Role: PRINCIPAL_INVESTIGATOR
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Deans R, Creighton SM, Liao LM, Conway GS. Timing of gonadectomy in adult women with complete androgen insensitivity syndrome (CAIS): patient preferences and clinical evidence. Clin Endocrinol (Oxf). 2012 Jun;76(6):894-8. doi: 10.1111/j.1365-2265.2012.04330.x.
Ahmed SF, Cheng A, Dovey L, Hawkins JR, Martin H, Rowland J, Shimura N, Tait AD, Hughes IA. Phenotypic features, androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome. J Clin Endocrinol Metab. 2000 Feb;85(2):658-65. doi: 10.1210/jcem.85.2.6337.
Bertelloni S, Meriggiola MC, Dati E, Balsamo A, Baroncelli GI. Bone Mineral Density in Women Living with Complete Androgen Insensitivity Syndrome and Intact Testes or Removed Gonads. Sex Dev. 2017;11(4):182-189. doi: 10.1159/000477599. Epub 2017 Jul 18.
Related Links
Access external resources that provide additional context or updates about the study.
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
200165
Identifier Type: -
Identifier Source: org_study_id
20-CH-0165
Identifier Type: -
Identifier Source: secondary_id